Aspreva agrees to $915M buyout offer

Switzerland's Galenica is buying out Canada's Aspreva Pharmaceuticals for $915 million. The deal values Aspreva's shares at $26 each, a 16 percent premium from yesterday's close. The buyout comes just weeks after Aspreva and Roche shelved plans to file for approval of CellCept, a new therapy for lupus. CellCept failed a late-stage trial, unable to demonstrate superiority to intravenous cyclophosphamide. That news took a serious bite out of Aspreva's stock value, paving the way to the deal announced today.

- see this release on the buyout

Related Articles:
Aspreva, Roche put CellCept on ice. Report
Aspreva's CellCept fails late-stage superiority study. Report
Aspreva Pharmaceuticals drug fails Phase III trial. Report
Buyouts a sign of industry's health. Report

Suggested Articles

Pfizer's eczema hopeful has been building its case to challenge Sanofi and Regeneron's Dupixent, but safety issues could stand in its way.

Cedrik Britten, M.D., becomes the biotech’s new chief medical officer to help run its adoptive cell therapy and TCR bispecifics platform.

Broad Institute researchers showed that base-editing the Tmc1 gene preserved hair cells that helped transmit sound in the ears of mice.